ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

After a year as licensee of Biotheus’s PD-L1 and VEGF-A-targeting bispecific BNT327, BioNTech has decided to buy the Chinese company outright, spending $800m upfront to do so. Though Biotheus has othe

Despite apparent lingering caution on the part of some biopharma multinationals over additional investments in China, Bayer and Eli Lilly have over the past few months both made similar moves to put n

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights

Gilead Sciences, Inc. is keeping mum about what prompted a partial clinical hold on its program to develop magrolimab in combination with Bristol Myers Squibb Company ’s Vidaza (azacitidine), apart